Method of treatment with tradipitant
AssigneesVanda Pharmaceuticals Inc., University of Kentucky Research Foundation
InventorsMihael H. Polymeropoulos, Gunther Birznieks, Sharon Walsh
Life of this patent
Estimating the term…
Abstract
Methods of treating an individual experiencing or at risk of experiencing an undesired consequence of opioid use, and of treating an individual who is experiencing or at risk of experiencing a craving for an opioid, as well as the use of the NK-1 receptor antagonist, tradipitant, in the treatment of such an individual are disclosed herein.
Claims20
A method of treating an individual who is experiencing or is at risk of experiencing an undesired consequence of opioid use, comprising:
- administering to said individual tradipitant:
- at a dose that is effective to achieve a plasma concentration of at least about 100 ng/ml or greater during said treatment, or at a dose that is 100-400 mg/day.
A method of treating an individual who is experiencing or is at risk of experiencing a craving for an opioid, comprising:
- administering to said individual tradipitant:
- at a dose that is effective to achieve a plasma concentration of at least about 100 ng/ml or greater during said treatment, or at a dose that is 150-400 mg/day.
Dependencies are inferred from the claim text.